● Recruiting

An Open-Label, Multicenter, Phase I Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of YY201 in Patients With Advanced Solid Tumors and Hematological Malignancies

Condition: Advanced Solid Tumor · Hematological Malignancy · Sponsor: Shanghai Yuyao Biotech Co., Ltd.

PhasePhase 1

Planned participants96

Who can joinAll sexes, 18 Years to 80 Years

Healthy volunteersNo

About this study

This is a multicenter, open-label, phase I clinical study of YY201 in the patients with relapsed/refractory lymphomas and relapsed/refractory large granular lymphocytic leukemia who failed or cannot tolerate standard treatment.

This description comes directly from the study's public registry record.

Talk to the study team

Ye Guo · 13501678472 · pattrickguo@gmail.com

Always discuss trial participation with your own doctor first.

Locations (1)

Shanghai East Hospital

Shanghai, Shanghai Municipality, China

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06225856